Slides from two journal articles and transcribed comments from Luca Gianni, MD and Eric P Winer, MD at a satellite symposium (12/12/09) and from a recent interview with Paul E Goss, MD, PhD (2/1/10)

Dr Gianni is Director of Medical Oncology 1 at Istituto Nazionale Tumori di Milano in Milan, Italy.

Dr Goss is Professor of Medicine at Harvard Medical School, Director of Breast Cancer Research at MGH Cancer Center and Co-director of the Breast Cancer Disease Program at Dana-Farber/Harvard Cancer Center in Boston, Massachusetts.

Dr Winer is Thompson Investigator in Breast Cancer Research, Chief of the Division of Women’s Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.

Presentations discussed in this issue:

Curigliano G et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27(34):5693-9. Abstract

Gonzalez-Angulo AM et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27(34):5700-6. Abstract

Go to previous Journal Club                                       Go to next Journal Club